August 27, 2019 • Seattle, WA

Presage Announces Collaboration with Bristol-Myers Squibb for Phase O Studies of Novel Cancer Agents Utilizing CIVO™ Technology

Presage Biosciences, a cancer biotechnology company pioneering a new cancer drug development approach using its CIVO™ multiplexed intratumoral microdosing platform, today announced it has entered into a research collaboration…

Learn More

May 02, 2019 • Seattle, WA

Presage Announces Collaboration with Celgene to Investigate Novel Agents with CIVO™ Technology

Research agreement to support Phase 0 tumor microdosing studies…

Learn More

July 17, 2018 • Seattle, WA

Presage Biosciences Closes Series D Financing with Takeda and Celgene, and Announces Appointment of Richard Klinghoffer, PhD as Chief Executive Officer

Presage Biosciences, a cancer biotechnology company pioneering the use of intratumoral microdosing for Phase 0 investigation of early development candidates, today announced that it has closed a Series D financing...…

Learn More

February 12, 2018 • Seattle, WA

Presage Biosciences Establishes Research Alliance with Codiak BioSciences Applying CIVO™ Intratumoral Microdosing to Exosome Therapeutics

Presage Biosciences, a cancer biotechnology company pioneering the use of intratumoral microdosing, today announced that it entered into a research alliance with Codiak BioSciences.…

Learn More

September 25, 2017 • Seattle, WA

Presage Biosciences Awarded Debut Grant from The Mark Foundation for Cancer Research to Support Immuno-Oncology Applications of CIVO™, an Intratumoral Microdosing Platform

The grant is aimed at advancing Presage’s next generation of intratumoral microdosing platform to assess immuno-oncology drug combinations.…

Learn More

September 05, 2017 • San Diego and Seattle

MEI Pharma Announces Exclusive License Agreement with Presage Biosciences for Voruciclib, An Oral, Selective CDK Inhibitor

MEI Pharma, Inc (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, today announced that it has entered into a license agreement with Presage Biosciences, Inc. for voruciclib…

Learn More

June 23, 2016 • Seattle, WA

Presage Biosciences Appoints David Johnson to Board of Directors

Presage Biosciences, an oncology company that is developing a novel drug development platform to assess drugs and combinations directly in patient tumors, announced today the appointment of David Johnson to its board of…

Learn More

April 19, 2016 • Seattle, WA

Presage Biosciences Presents Data Demonstrating Tumor Growth Inhibition by Voruciclib and Proteasome Inhibitors Superior to Single Agents in Model of Triple Negative Breast Cancer

Presage Biosciences, an oncology company that is developing a novel drug development platform to assess drug combinations directly in patient tumors, will present preclinical data showing that the company’s clinical-stage…

Learn More

April 14, 2016 • Seattle, WA

Presage Biosciences Extends Research Collaboration with Takeda to Discover Novel Cancer Drug Combinations

Presage Biosciences, an oncology company that has established a novel drug development approach to assess drug combinations directly in-patient tumors, announced today that is has entered into a multi-year extension of its …

Learn More

January 11, 2016 • Seattle, WA

Presage Biosciences Appoints Oncology Experts to Newly Created Medical Advisory Panel

Presage Biosciences, an oncology company pioneering a radical new drug development approach that incorporates human efficacy data much earlier in development and clinical trials, announced today the formation of a Medical…

Learn More

November 24, 2015 • Seattle, WA

Presage Biosciences In-Licenses Clinical Stage Drug Program

Presage Biosciences, an oncology company pioneering a radical new drug development approach that incorporates human efficacy data much earlier in development and clinical trials, announced today that it has in-licensed …

Learn More

November 24, 2015 • Seattle, WA

Presage Biosciences Appoints Two New Directors

Presage Biosciences, an oncology company pioneering a radical new drug development approach that incorporates human efficacy data much earlier in development and clinical trials, announced today the appointment of Tachi…

Learn More

August 20, 2015 • Seattle, WA

Presage Biosciences Receives Strategic Investment from Takeda

Presage Biosciences, an oncology company pioneering a radical new drug development approach that incorporates human efficacy data much earlier in development and clinical trials, today announced that it has secured a …

Learn More

April 22, 2015 • Seattle, WA

Study finds that microinjection platform enables assessment of multiple cancer drugs directly in tumors, predicts systemic response

A newly developed technology for simultaneously comparing response to multiple cancer drugs or combinations while a tumor is still in a patient’s body has been shown to accurately predict systemic response to the drugs, …

Learn More

March 20, 2015 • Seattle, WA

Presage Biosciences Granted Sixth U.S. Patent for CIVO™ Arrayed Microinjection Technology for Comparing Multiple Drugs in a Single Living Tumor

Presage Biosciences, an oncology company pioneering a radical new drug development approach that incorporates human efficacy data much earlier in development and clinical trials, announced today that the U.S. Patent and Trade…

Learn More

March 16, 2015 • Seattle, WA

Presage Biosciences Appoints Brad Margus to Board of Directors

Presage Biosciences, an oncology company pioneering a radical new drug development approach that incorporates human efficacy data much earlier in development and clinical trials, announced today the appointment of Brad Margus…

Learn More

November 12, 2014 • Seattle, WA

Presage Biosciences Expands Collaboration with Takeda for CIVO™ Technology to Assess Cancer Drugs Directly in Solid Tumors

Presage Biosciences, an oncology company developing a radical new testing approach that incorporates human data much earlier in drug development and clinical trials, announced today that it has expanded its cancer research …

Learn More

October 21, 2014 • Seattle, WA

Presage Biosciences Granted Fifth U.S. Patent for CIVO™ Arrayed Microinjection Technology for Comparing Multiple Drugs in a Single Living Tumor

Presage Biosciences, an oncology company developing a radical new testing approach that incorporates human efficacy data much earlier in drug development and clinical trials, announced today that the U.S. Patent and Trademark…

Learn More

April 08, 2014 • Seattle, WA

Presage Biosciences Presents Proof-of-Concept Data for CIVO™ Preclinical Assessment Platform at AACR 2014 Annual Meeting

Presage Biosciences, a biotechnology company focused on bringing the earliest human efficacy data possible into cancer drug development, presented preclinical data showing that microinjection of several standard-of-care …

Learn More

September 24, 2013 • Seattle, WA

Presage Biosciences Named a “Fierce 15” Biotech Company of 2013 by FierceBiotech

Presage Biosciences, a leader in precision oncology, has been named by FierceBiotech as one of 2013’s Fierce 15 biotechs, designating it as one of the most promising private biotechnology companies in the industry. This is…

Learn More

April 19, 2013 • Seattle, WA

Presage Biosciences Announces First Patient in Clinical Trial of CIVO™ Precision Oncology

Presage Biosciences, a leader in precision oncology, today announced the initiation of a clinical trial and the first patient use of CIVO™, the company’s precision oncology platform designed to improve treatment decisions for…

Learn More

March 05, 2013 • Seattle, WA

Presage Biosciences Announces Strategic Research Alliance with Celgene Corporation

Presage Biosciences, a leader in discovering effective cancer drug combinations, today announced that it has entered into a strategic collaboration agreement with Celgene Corporation under which Presage and Celgene will take …

Learn More

April 05, 2012 • Seattle, WA

Presage Biosciences and Millennium Pharmaceuticals Enter Into Cancer Research Agreement

Presage Biosciences, a leader in identifying clinically viable oncology drug combinations, today announced that it has entered into a cancer research agreement with Millennium: The Takeda Oncology Company. The research agreem…

Learn More

December 15, 2011 • Seattle, WA

Presage Biosciences Appoints Jim Towne as CEO

Presage Biosciences, a privately held biotechnology company that works with oncology-focused pharmaceutical companies through strategic alliances using its patented three-dimensional in vivo drug analysis platform, announced …

Learn More